Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DMAC vs VSTM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 55.0 HOLD), While VSTM Leads 3–2 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: DMAC 2 – 3 VSTM (1 Tie) Matrix Metrics: DMAC 3 – 5 VSTM

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Verastem, Inc. (VSTM) on higher Unified Composite conviction (46.3/100 HOLD vs. 55.0/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while VSTM wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus VSTM at $7.88 (N/M Forward P/E, -193.7% operating margin).

  • Composite vs. Pillar Nuance: While VSTM currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -193.7% operating margin) and revenue trajectory (+0.0% vs. +113.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMAC vs VSTM
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $9.24 · SMA50: $8.24
VSTM NASDAQ
Verastem, Inc.
Pharmaceutical Preparations
$7.88
-3.67% 1D
Market Cap $1.1B
TTM Revenue $100M
Forward P/E N/M
Beta / 30D Vol 1.11β · 71% Vol
Unified Composite Score
55.0 / 100 HOLD
Tech 26.0 Fund 52.0 Flow 64.0 Mom 70.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 39.6 · SMA20: $9.31 · SMA50: $8.48

6-Pillar Scorecard Institutional Category Breakdown (DMAC 2 – 3 VSTM)

Columns: Metric · DMAC · VSTM
1. Valuation Multiples VSTM
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 10.2x
2. Growth & Scale VSTM
Revenue Growth (YoY) +0.0% +113.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $100M
Market Cap $503.1M $1.1B
3. Profitability & Quality DMAC
Gross Margin N/A 87.2%
Operating Margin 0.0% -193.7%
Net Profit Margin 0.0% -178.4%
Return on Equity (ROE) -114.6% -471.2%
4. Balance Sheet & Cash Flow VSTM
Cash Generation (TTM) -$32M -$168M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.9M Net Cash $44M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 106.3% (14th %ile) 96.8% (10th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMAC (3) vs VSTM (5)
Institutional Metric DMAC VSTM Criterion Row Edge
Market Capitalization
Scale
$503.1M $1.1B Larger Scale VSTM
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +113.6% Higher Growth VSTM
Operating Margin (TTM)
Profitability
0.0% -193.7% Higher Margin DMAC
Net Profit Margin
Profitability
0.0% -178.4% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-114.6% -471.2% Higher ROE DMAC
52-Week Range Position
Momentum
55% ($5–$11) 60% ($3–$11) Stronger Trend VSTM
Beta / 30D Volatility
Risk Regime
1.74β · 98% Vol 1.11β · 71% Vol Lower Realized Risk VSTM
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 55.0 / 100 (HOLD) Higher Composite VSTM
Trailing 12M Revenue (USD)
Operating Scale
N/A $100M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 87.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 10.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($4.9M Net Cash) -$168M ($44M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +20.06 pp
DMAC: +11.16% · VSTM: -8.9%
3M Horizon DMAC +21.25 pp
DMAC: +27.31% · VSTM: +6.06%
6M Horizon VSTM +36.83 pp
DMAC: +48.15% · VSTM: +84.98%
1Y Horizon DMAC +58.1 pp
DMAC: +55.26% · VSTM: -2.84%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DMAC Revenue VSTM Revenue DMAC Op. Margin VSTM Op. Margin Margin Leader
FY2018 $0M $30M -1352.2% -354.8% VSTM
FY2019 N/A $20M N/A -758.1% VSTM
FY2020 N/A $90M N/A -55.8% VSTM
FY2021 N/A $0M N/A -2991.2% VSTM
FY2022 N/A $0M N/A -2809.6% VSTM
FY2024 N/A $10M N/A -1149.6% VSTM
FY2025 N/A $30M N/A -550.3% VSTM

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VSTM CONSOLIDATION
50d in phase · OBV NEUTRAL
Current IV 96.8%
IV Percentile 10th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VSTM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VSTM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and -193.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DMAC vs VSTM Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Verastem, Inc. (VSTM) on higher Unified Composite conviction (46.3/100 HOLD vs. 55.0/100 HOLD) after splitting the core matrix 3–5 (led by Profitability & Quality, Options & Positioning), while VSTM wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus VSTM at $7.88 (N/M Forward P/E, -193.7% operating margin). Composite vs. Pillar Nuance: While VSTM currently prints a higher short-term Unified Composite Score (55.0/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -193.7% operating margin) and revenue trajectory (+0.0% vs. +113.6% YoY).

VSTM leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VSTM at +113.6% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (87.2% gross margin, -193.7% operating margin). Across the 7-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while VSTM shifted +0.0%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VSTM.

VSTM screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas VSTM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 10.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus VSTM (-471.2% ROE) capital efficiency.

In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, VSTM carries 96.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.11β · 71% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.